冠心病合理用药指南(第2版)

2018-03-01 国家卫生计生委合理用药专家委员会 《中国医学前沿杂志(电子版)》

2018年3月1日,由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会,经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。

中文标题:

冠心病合理用药指南(第2版)

发布日期:

2018-03-01

简要介绍:

2018年3月1日,由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会,经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。指南工作 组针对这些核心问题制定了具体的文献检索和评价 策略,综合评价、筛选出相关文献。

相关资料下载:
[AttachmentFileName(sort=1, fileName=_冠心病合理用药指南(第2版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=9d70f1c00216e3cd, title=冠心病合理用药指南(第2版), enTitle=, guiderFrom=《中国医学前沿杂志(电子版)》, authorId=0, author=, summary=2018年3月1日,由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会,经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。, cover=https://img.medsci.cn/2021829/1630250153722_5579292.png, journalId=0, articlesId=null, associationId=1325, associationName=国家卫生计生委合理用药专家委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Mar 01 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>2018年3月1日,由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会,经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。指南工作 组针对这些核心问题制定了具体的文献检索和评价 策略,综合评价、筛选出相关文献。</p> </div> </div> </div>, tagList=[TagDto(tagId=703, tagName=冠心病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=703, guiderKeyword=冠心病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4374, appHits=918, showAppHits=0, pcHits=678, showPcHits=3445, likes=6, shares=115, comments=29, approvalStatus=1, publishedTime=Mon Aug 30 09:48:22 CST 2021, publishedTimeString=2018-03-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Aug 29 23:16:01 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 11:25:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_冠心病合理用药指南(第2版).pdf)])
_冠心病合理用药指南(第2版).pdf
下载请点击:
评论区 (23)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了,很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-10-19 ms3000000190198551

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了,很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-06-17 ms6000000225486324

    学习了,很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了,很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-03-05 1e1275afm36(暂无匿称)

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了,很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-02-21 139fe8b3m05暂无昵称

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了,很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 ms2000001716855301

    好的

    0